signals involved in each model are listed in Table S1. All these discriminant models were able to classify the samples into four groups, corresponding to NL, AC, SC and LC. Percentages of correctly classified samples by each model and leave-one-out crossvalidation percentages of correctly classified samples are displayed in Table S1. A second Stepwise Discriminant Analysis was performed with peaks CAY10505 included in the four Mx-Mt Discriminant models to avoid including noisy mass signals in the analysis. The Global Model included peaks and correctly classified 98.0 of the samples in the LOOCV. We performed a Supervised Hierarchical Centroid Linkage Clustering using the 9 peaks included in the Global Model. As shown in S-2367 distributor Figure 1, there are two main clusters, separating normal lung samples from most tumor samples. However, there is not perfect separation between histological subtypes. With the aim of selecting mass signals that could characterize samples from one histological subtype when compared with the other subtypes of NSCLC samples, AdaBoost decision tree-based classifier ensemble was performed. Three independent analyses were performed: AC vs., LC vs. and SC vs., using data in Set 1 as training set and data in Set 2 as test set from the final DHB-Ga peak list. The area under the curve from ROC was calculated for each comparison in both training and test set. The relative influence of each peak in model generation was obtained. The area under the ROC curve and top peaks for each comparison are shown in Table 1. MS/MS identification of some m/z peaks selected by discriminant and AdaBoost analyses was performed by MALDITOF/ TOF. In order to evaluate differences in identified peptide signals among histological subtypes, ANOVA and Kruskal-Wallis analyses were performed. b-globin mass signals showed a significantly decreased intensity in tumor samples when compared with normal lung ones, while GAPDH and bactin peaks showed increased intensity in tumor samples. CK8 peak intensity decreased in large cell carcinomas when compared with adenocarcinoma and squamous cell carcinoma samples. The pattern of expression by immunohistochemistry of some of these markers was analyzed. The Human Protein Atlas shows expression and l
